Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis

Thrombosis Research

Volumn 125, Issue 3, 2010, Pages 210-215

  Stavrou, Evi ^a   Schmaier, Alvin H ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; PROTEINASE;

ANGIOGENESIS; BLOOD CLOTTING FACTOR 12 DEFICIENCY; ENZYME ACTIVE SITE; HEMOSTASIS; HUMAN; KRINGLE DOMAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; THROMBUS; TISSUE INJURY;

ANIMALS; BLOOD COAGULATION; FACTOR XII; FACTOR XII DEFICIENCY; HEMOSTASIS; MICE; THROMBOSIS;

EID: 76949094364     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.11.028     Document Type: Review

References (66)

1. Ratnoff O.D., and Colopy J.E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34 4 (Apr 1955) 602-613
2. Davie E.W., and Ratnoff O.D. Waterfall Sequence for Intrinsic Blood Clotting. Science 145 (Sep 18 1964) 1310-1312
3. Ghebrehiwet B., Silverberg M., and Kaplan A.P. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153 3 (Mar 1 1981) 665-676
4. Citarella F., Tripodi M., Fantoni A., Bernardi F., Romeo G., and Rocchi M. Assignment of human coagulation factor XII (fXII) to chromosome 5 by cDNA hybridization to DNA from somatic cell hybrids. Hum Genet 80 4 (Dec 1988) 397-398
5. Cool D.E., and MacGillivray R.T. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5'-flanking region. J Biol Chem 262 28 (Oct 5 1987) 13662-13673
6. Petersen T.E., Thogersen H.C., Skorstengaard K., Vibe-Pedersen K., Sahl P., Sottrup-Jensen L., et al. Partial primary structure of bovine plasma fibronectin: three types of internal homology. Proc Natl Acad Sci U S A 80 1 (Jan 1983) 137-141
7. Yamada K.M. Cell surface interactions with extracellular materials. Annu Rev Biochem 52 (1983) 761-799
8. Clarke B.J., Cote H.C., Cool D.E., Clark-Lewis I., Saito H., Pixley R.A., et al. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 264 19 (Jul 5 1989) 11497-11502
9. Samuel M., Samuel E., and Villanueva G.B. Histidine residues are essential for the surface binding and autoactivation of human coagulation factor XII. Biochem Biophys Res Commun 191 1 (Feb 26 1993) 110-117
10. Pixley R.A., Stumpo L.G., Birkmeyer K., Silver L., and Colman R.W. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 262 21 (Jul 25 1987) 10140-10145
11. Citarella F., Ravon D.M., Pascucci B., Felici A., Fantoni A., and Hack C.E. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 238 1 (May 15 1996) 240-249
12. Citarella F., Fedele G., Roem D., Fantoni A., and Hack C.E. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood 92 11 (Dec 1 1998) 4198-4206
13. Baglia F.A., Jameson B.A., and Walsh P.N. Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI. J Biol Chem 268 6 (Feb 25 1993) 3838-3844
14. Mahdi F., Madar Z.S., Figueroa C.D., and Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 99 10 (May 15 2002) 3585-3596
15. Henderson L.M., Figueroa C.D., Muller-Esterl W., and Bhoola K.D. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 84 2 (Jul 15 1994) 474-482
16. Bradford H.N., Pixley R.A., and Colman R.W. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 275 30 (Jul 28 2000) 22756-22763
17. Hasan A.A., Zisman T., and Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A 95 7 (Mar 31 1998) 3615-3620
18. Mahdi F., Shariat-Madar Z., Todd III R.F., Figueroa C.D., and Schmaier A.H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 97 8 (Apr 15 2001) 2342-2350
19. Rojkaer R., and Schousboe I. Partial identification of the Zn2+-binding sites in factor XII and its activation derivatives. Eur J Biochem 247 2 (Jul 15 1997) 491-496
20. Cool D.E., Edgell C.J., Louie G.V., Zoller M.J., Brayer G.D., and MacGillivray R.T. Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa. J Biol Chem 260 25 (Nov 5 1985) 13666-13676
21. Cohen S. Epidermal growth factor. In Vitro Cell Dev Biol 23 4 (Apr 1987) 239-246
22. Chien P., Pixley R.A., Stumpo L.G., Colman R.W., and Schreiber A.D. Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest 82 5 (Nov 1988) 1554-1559
23. Gordon E.M., Venkatesan N., Salazar R., Tang H., Schmeidler-Sapiro K., Buckley S., et al. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A 93 5 (Mar 5 1996) 2174-2179
24. Schmeidler-Sapiro K.T., Ratnoff O.D., and Gordon E.M. Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. Proc Natl Acad Sci U S A 88 10 (May 15 1991) 4382-4385
25. Fernando A.N., Fernando L.P., Fukuda Y., and Kaplan A.P. Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 289 1 (Jul 2005) H251-H257
26. Citarella F., te Velthuis H., Helmer-Citterich M., and Hack C.E. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII-an immunochemical and homology modeling approach. Thromb Haemost 84 6 (Dec 2000) 1057-1065
27. Revak S.D., Cochrane C.G., and Griffin J.H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 59 6 (Jun 1977) 1167-1175
28. Fujikawa K., and McMullen B.A. Amino acid sequence of human beta-factor XIIa. J Biol Chem 258 18 (Sep 25 1983) 10924-10933
29. Dunn J.T., Silverberg M., and Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem 257 4 (Feb 25 1982) 1779-1784
30. Rojkjaer R., Hasan A.A., Motta G., Schousboe I., and Schmaier A.H. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 80 1 (Jul 1998) 74-81
31. Wiggins R.C., and Cochrane C.C. The autoactivation of rabbit Hageman factor. J Exp Med 150 5 (Nov 1 1979) 1122-1133
32. Samuel M., Pixley R.A., Villanueva M.A., Colman R.W., and Villanueva G.B. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267 27 (Sep 25 1992) 19691-19697
33. Chen X., Wang J., Paszti Z., Wang F., Schrauben J.N., Tarabara V.V., et al. Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Anal Bioanal Chem 388 1 (May 2007) 65-72
34. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358 23 (Jun 5 2008) 2457-2467
35. Kannemeier C., Shibamiya A., Nakazawa F., Trusheim H., Ruppert C., Markart P., et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104 15 (Apr 10 2007) 6388-6393
36. Smith S.A., Mutch N.J., Baskar D., Rohloff P., Docampo R., and Morrissey J.H. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 103 4 (Jan 24 2006) 903-908
37. Maas C., Govers-Riemslag J.W., Bouma B., Schiks B., Hazenberg B.P., Lokhorst H.M., et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118 9 (Sep 2008) 3208-3218
38. van der Meijden P.E., Munnix I.C., Auger J.M., Govers-Riemslag J.W., Cosemans J.M., Kuijpers M.J., et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 114 4 (Jul 23 2009) 881-890
39. Matsumoto K., Yamamoto T., Kamata R., and Maeda H. Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem 96 3 (Sep 1984) 739-749
40. Kaminishi H., Hamatake H., Cho T., Tamaki T., Suenaga N., Fujii T., et al. Activation of blood clotting factors by microbial proteinases. FEMS Microbiol Lett 121 3 (Sep 1 1994) 327-332
41. Forbes C.D., Pensky J., and Ratnoff O.D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med 76 5 (Nov 1970) 809-815
42. Pixley R.A., Schmaier A., and Colman R.W. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys 256 2 (Aug 1 1987) 490-498
43. Stead N., Kaplan A.P., and Rosenberg R.D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 251 21 (1976 Nov 10) 6481-6488
44. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., and Davis III A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 8 (2002 Apr) 1057-1063
45. Cichon S., Martin L., Hennies H.C., Muller F., Van Driessche K., Karpushova A., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79 6 (2006 Dec) 1098-1104
46. Farsetti A., Misiti S., Citarella F., Felici A., Andreoli M., Fantoni A., et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136 11 (1995 Nov) 5076-5083
47. Farsetti A., Moretti F., Narducci M., Misiti S., Nanni S., Andreoli M., et al. Orphan receptor hepatocyte nuclear factor-4 antagonizes estrogen receptor alpha-mediated induction of human coagulation factor XII gene. Endocrinology 139 11 (1998 Nov) 4581-4589
48. Inoue Y., Peters L.L., Yim S.H., Inoue J., and Gonzalez F.J. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med 84 4 (Apr 2006) 334-344
49. Spronk H., Heemskerk J.W., Ten Cate H., Knetch M.L., Gailani D., Pawlinski R., et al. Feedback activation of factor XI by thombin is essential for haemostasis in vivo. J Thromb Haemost 7 s2 (2009) 1-316
50. Proctor R.R., and Rapaport S.I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 36 (Sep 1961) 212-219
51. Renne T., Pozgajova M., Gruner S., Schuh K., Pauer H.U., Burfeind P., et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202 2 (Jul 18 2005) 271-281
52. Kleinschnitz C., Stoll G., Bendszus M., Schuh K., Pauer H.U., Burfeind P., et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203 3 (Mar 20 2006) 513-518
53. Halbmayer W.M., Mannhalter C., Feichtinger C., Rubi K., and Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 68 3 (Sep 7 1992) 285-290
54. Koster T., Rosendaal F.R., Briet E., and Vandenbroucke J.P. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 87 2 (Jun 1994) 422-424
55. Santamaria A., Mateo J., Tirado I., Oliver A., Belvis R., Marti-Fabregas J., et al. Homozygosity of the T allele of the 46 C->T polymorphism in the F12 gene is a risk factor for ischemic stroke in the Spanish population. Stroke 35 8 (Aug 2004) 1795-1799
56. Soria J.M., Almasy L., Souto J.C., Bacq D., Buil A., Faure A., et al. A quantitative-trait locus in the human factor XII gene influences both plasma factor XII levels and susceptibility to thrombotic disease. Am J Hum Genet 70 3 (Mar 2002) 567-574
57. Zito F., Lowe G.D., Rumley A., McMahon A.D., and Humphries S.E. Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis 165 1 (Nov 2002) 153-158
58. Endler G., Mannhalter C., Sunder-Plassmann H., Lalouschek W., Kapiotis S., Exner M., et al. Homozygosity for the C->T polymorphism at nucleotide 46 in the 5' untranslated region of the factor XII gene protects from development of acute coronary syndrome. Br J Haematol 115 4 (Dec 2001) 1007-1009
59. Colhoun H.M., Zito F., Norman Chan N., Rubens M.B., Fuller J.H., and Humphries S.E. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 163 2 (Aug 2002) 363-369
60. Doggen C.J., Rosendaal F.R., and Meijers J.C. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 108 13 (Dec 15 2006) 4045-4051
61. Gailani D., and Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?. J Thromb Haemost 5 6 (Jun 2007) 1106-1112
62. Sabater-Lleal M., Chillon M., Mordillo C., Martinez A., Gil E., Mateo J., et al. Combined cis-regulator elements as important mechanism affecting FXII plasma levels. Thromb Res (Sep 26 2009)
63. Sladek F.M., Ruse Jr. M.D., Nepomuceno L., Huang S.M., and Stallcup M.R. Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. Mol Cell Biol 19 10 (Oct 1999) 6509-6522
64. McMullen B.A., and Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem 260 9 (May 10 1985) 5328-5341
65. Schousboe I. Contact activation in human plasma is triggered by zinc ion modulation of factor XII (Hageman factor). Blood Coagul Fibrinolysis 4 5 (Oct 1993) 671-678
66. Ravon D.M., Citarella F., Lubbers Y.T., Pascucci B., and Hack C.E. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 86 11 (Dec 1 1995) 4134-4143